Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Operating Leases (2019 - 2025)

Coherus Oncology's Operating Leases history spans 7 years, with the latest figure at $1.9 million for Q3 2025.

  • For Q3 2025, Operating Leases fell 47.93% year-over-year to $1.9 million; the TTM value through Sep 2025 reached $1.9 million, down 47.93%, while the annual FY2024 figure was $3.3 million, 38.33% down from the prior year.
  • Operating Leases for Q3 2025 was $1.9 million at Coherus Oncology, down from $2.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $9.2 million in Q1 2021 and bottomed at $1.4 million in Q3 2023.
  • The 5-year median for Operating Leases is $4.7 million (2024), against an average of $4.9 million.
  • The largest annual shift saw Operating Leases crashed 76.55% in 2023 before it soared 160.24% in 2024.
  • A 5-year view of Operating Leases shows it stood at $7.3 million in 2021, then tumbled by 30.41% to $5.0 million in 2022, then grew by 5.59% to $5.3 million in 2023, then plummeted by 38.33% to $3.3 million in 2024, then tumbled by 40.78% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Operating Leases are $1.9 million (Q3 2025), $2.4 million (Q2 2025), and $2.9 million (Q1 2025).